

Ashland Inc. Reports Preliminary Fiscal Second-Quarter EPS from Continuing Operations of 25 Cents, Adjusted EPS of \$1.02 Excluding Key Items

COVINGTON, Ky., April 27, 2010 /PRNewswire via COMTEX News Network/ -- Ashland Inc. (NYSE: ASH) today announced preliminary (1) results for the quarter ended March 31, 2010, the second quarter of its 2010 fiscal year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040113/ASHLANDLOGO)

Quarterly Highlights

(in millions except per-share amounts)		ter Ended 1 31, 2010	Quarter Endeo March 31, 200		
Operating income Adjusted EBITDA*	\$	151 224	\$	112 221	
Diluted earnings per share (EPS) From continuing operations Less: key items*	\$	0.25 0.77	\$	0.65 0.20	
Adjusted*	\$	1.02	\$	0.85	
Cash flows provided by operating activities from continuing operations Free cash flow*	\$	183 138	\$	220 173	
* See Tables 5, 6 and 7 for definitions and U	.S. GAA	P reconcilia	tions.		

Fiscal Second-Quarter GAAP(2) Results

For its 2010 second quarter, Ashland reported sales of \$2,248 million, operating income of \$151 million and net income of \$22 million (27 cents per share). Net income was favorably affected by \$2 million aftertax (2 cents per share) from discontinued operations. Cash flows provided by operating activities from continuing operations amounted to \$183 million.

Adjusted Results

Adjusting for the impact of key items in both the current and prior-year quarters, Ashland's results for the March 2010 quarter versus the March 2009 quarter were as follows:

- sales increased 13 percent from \$1,990 million to \$2,248 million;
- adjusted operating income increased 13 percent from \$134 million to \$151 million;
- adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) increased 1 percent from \$221 million to \$224 million; and
- adjusted EPS from continuing operations increased 20 percent from 85 cents to \$1.02.

Key Items

Two key items affected results for the March 2010 quarter. First, accelerated amortization of debt issuance costs and prepayment penalties associated with Ashland's debt refinancing resulted in both a \$62 million noncash charge and a \$4 million cash expense (54 cents negative EPS impact combined). Second, the enactment of the U.S. Patient Protection and Affordable Care Act resulted in a \$19 million aftertax charge (23 cents negative EPS impact), composed of a \$14 million income tax expense and a \$5 million net loss on divestitures.

In total, key items had a net unfavorable EPS impact on continuing operations of 77 cents in the March 2010 quarter. In the year-ago quarter, three key items combined for a net unfavorable impact on earnings of 20 cents per share. Refer to Table 5 of the accompanying financial statements for details of key items in both periods.

Results also included noncash intangible amortization expense of \$17 million pretax (14 cents negative EPS impact) in the March 2010 quarter and \$21 million pretax (18 cents negative EPS impact) in the March 2009 quarter. Amounts in both periods primarily reflect the addition of intangible assets from the Hercules acquisition.

Performance Summary

Commenting on the March 2010 quarter, Chairman and Chief Executive Officer James J. O'Brien said, "Ashland's results reflect

significant volume increases across our businesses, as well as the progress we have made in resizing our cost structure during the past two years. These were important factors in our ability to maintain EBITDA and generate \$138 million of free cash flow despite a rapid increase in raw material costs averaging 7 percent during the March quarter alone. All of our businesses have been implementing significant price increases to offset these escalating costs. Once raw materials stabilize, we expect our pricing to fully recover the cost increases."

Commenting on the performance of Ashland's commercial units, O'Brien said, "In particular, Ashland Aqualon Functional Ingredients improved its volume and profitability dramatically versus the March 2009 quarter on a comparable basis, while Ashland Consumer Markets (Valvoline) continued to deliver strong results, producing its fifth straight quarter with an EBITDA margin in excess of 18 percent."

O'Brien concluded, "We completed the refinancing and restructuring of our debt on March 31. This reduces our interest expense going forward by approximately \$50 million per year. In addition, the last major step in the integration of Hercules was completed earlier this month, as we successfully moved the acquired businesses onto Ashland's ERP platform. Essentially all of Ashland's businesses are now on a unified, global operating system."

Business Performance

In order to aid understanding of Ashland's ongoing business performance, the results of Ashland's business segments are presented on an adjusted basis and EBITDA is reconciled to GAAP in Table 7 of this news release.

Ashland Aqualon Functional Ingredients recorded sales of \$240 million in the March 2010 quarter, 8 percent above the year-ago quarter. Volume increased 36 percent excluding the amounts associated with the Pinova business divested in January 2010 and with a renegotiated supply contract in the oilfield sector in the prior-year period. Volumes increased significantly in every market, with the regulated, energy and coatings-additives markets all increasing about 40 percent on a comparable basis. On the same basis, volumes increased dramatically in all regions. Gross profit as a percent of sales of 34.9 percent was a 530-basis-point improvement over the March 2009 quarter. Selling, general and administrative and research and development (SG&A) expenses declined 2 percent versus the prior-year quarter. In total, Functional Ingredients' EBITDA in the March 2010 quarter increased 23 percent versus the prior March quarter, to \$58 million, and represented 24.2 percent of sales, a 310-basis-point improvement.

Ashland Hercules Water Technologies' sales grew to \$449 million in the March 2010 quarter, a 4-percent increase over the same yearago quarter. Excluding the marine business sold in August 2009, sales grew 13 percent. On the same basis, growth was strongest in Latin America, at 24 percent, while Europe and Asia Pacific grew by 17 percent and 16 percent, respectively. Sales in North America increased by 9 percent. Gross profit as a percent of sales was 34.5 percent, a 190-basis-point improvement over the March 2009 quarter. SG&A expenses declined 3 percent. EBITDA of \$52 million was 37 percent above the prior-year quarter and represented 11.6 percent of sales, a 280-basis-point improvement.

Ashland Performance Materials' sales of \$304 million increased 17 percent versus the same prior-year quarter, while volume per day was up 19 percent. Sequentially, volume improved 10 percent. Volume growth was broad-based across regions and markets. Gross profit as a percent of sales decreased 430 basis points from the prior-year quarter to 16.5 percent, due primarily to rapidly rising raw material costs. To offset these cost increases, Performance Materials has announced and is implementing significant price increases. However, the lag between cost increases and realization of selling price increases led to the margin compression during the quarter. SG&A expenses rose only 4 percent in spite of the 19-percent volume increase, providing early evidence of the operating leverage within the business. EBITDA was \$18 million in the March 2010 quarter, down 22 percent versus the prior-year March quarter, and EBITDA as a percent of sales declined 300 basis points to 5.9 percent.

Ashland Consumer Markets' sales increased 6 percent over the year-ago March quarter, to \$430 million, and total lubricant volume increased by 16 percent. Same-store sales at Valvoline Instant Oil Change increased 4 percent over the prior year. Gross profit was 33.0 percent of sales in the March 2010 quarter versus 32.2 percent in the year-ago quarter and 33.9 percent in the December 2009 quarter. SG&A expenses rose 16 percent over the year-ago March quarter, largely the result of higher pension, benefit and incentive costs, along with higher advertising expenses. Sequentially, SG&A increased 4 percent. Overall, Consumer Markets' quarterly EBITDA was \$78 million, as compared with \$75 million in the year-ago March quarter and \$76 million in the December 2009 quarter. The EBITDA margin was 18.1 percent in the March 2010 quarter, the fifth consecutive quarter in excess of 18 percent.

Ashland Distribution's sales for the March 2010 quarter increased 23 percent to \$857 million, and volume per day increased 8 percent versus the March 2009 quarter. Gross profit as a percent of sales was 9.3 percent versus 12.8 percent in the prior March quarter. The March 2009 quarter included an \$11 million benefit from a quantity LIFO adjustment that was not repeated in the 2010 quarter. SG&A expenses rose 8 percent versus the prior-year quarter as previously implemented cost reductions were more than offset by increased pension, benefit and incentive costs. As a result, EBITDA declined 37 percent versus the prior-year March quarter, to \$24 million, and was 2.8 percent of sales. Sequentially, EBITDA was up 85 percent on an 8-percent increase in volume, while SG&A expense rose only 3 percent. As a result of this operating leverage, the EBITDA margin increased by 100 basis points.

Outlook

Commenting on Ashland's outlook, O'Brien said, "We are continuing to demonstrate our ability to generate the consistent earnings, gross margins and cash flows characteristic of specialty chemicals companies. By eliminating more than \$400 million from our cost structure during the past two years, we have positioned the company to take advantage of improving demand. Over the last few quarters, we have begun to benefit from economic growth. In the short term, the full benefit of operating leverage has been tempered

by significant raw material cost escalation. Once raw materials stabilize and our increased pricing recaptures these costs, the favorable impact of improving volumes on operating leverage should become much more evident."

Conference Call Webcast

Today at 9 a.m. EDT, Ashland will provide a live webcast of its second-quarter conference call with securities analysts. The webcast will be accessible through Ashland's website, www.ashland.com. Following the live event, an archived version of the webcast will be available for 12 months at http://investor.ashland.com.

Use of Non-GAAP Measures

This news release includes certain non-GAAP measures. Such measurements are not prepared in accordance with generally accepted accounting principles (GAAP) and should not be construed as an alternative to reported results determined in accordance with GAAP. Management believes the use of such non-GAAP measures assists investors in understanding the ongoing operating performance of the company and its segments. The non-GAAP information provided may not be consistent with the methodologies used by other companies. All non-GAAP information is reconciled with reported GAAP results in Tables 5, 6 and 7 of the financial statements provided below.

About Ashland

Ashland Inc. (NYSE: ASH) provides specialty chemical products, services and solutions for many of the world's most essential industries. Serving customers in more than 100 countries, it operates through five commercial units: Ashland Aqualon Functional Ingredients, Ashland Hercules Water Technologies, Ashland Performance Materials, Ashland Consumer Markets (Valvoline) and Ashland Distribution. To learn more about Ashland, visit <u>www.ashland.com</u>.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon a number of assumptions, including those mentioned within this news release. Performance estimates are also based upon internal forecasts and analyses of current and future market conditions and trends; management plans and strategies; operating efficiencies and economic conditions; and legal proceedings and claims (including environmental and asbestos matters). Other risks and uncertainties include those that are described in filings made by Ashland with the Securities and Exchange Commission, including its most recent Forms 10-K and 10-Q, which are available on Ashland's website at http://investor.ashland.com or at www.sec.gov. Ashland believes its expectations are reasonable, but cannot assure they will be achieved. Forward-looking information may prove to be inaccurate, and actual results may differ significantly from those anticipated. Ashland is not obligated to subsequently update or revise the forward-looking statements made in this news release.

(1) Preliminary Results

Financial results are preliminary until Ashland's quarterly report on Form 10-Q is filed with the U.S. Securities and Exchange Commission.

(2) Generally accepted accounting principles (U.S.)

Ashland Inc. and Consolidated Subsidiaries

STATEMENTS OF CONSOLIDATED INCOME

(In millions except per share data - preliminary and unaudited)

(nths ended ch 31	Six months ended March 31				
	2010	2009	2010	2009 (e)			
SALES	\$ 2,248	\$ 1,990	\$ 4,268	\$ 3,956			
COSTS AND EXPENSES							
Cost of sales (a)	1,738	1,531	3,272	3,172			
Selling, general and administrative expenses (a)	354	329	688	646			
Research and development expenses (b)	20	23	40	50			
	2,112	1,883	4,000	3,868			
EQUITY AND OTHER INCOME	15	5	29	17			
OPERATING INCOME	151	112	297	105			
Net interest and other financing expense (c)	(103)	(54)	(145)	(82)			
Net loss on divestitures	(5)	(1)	(5)	-			
Other income and expenses (d)	-	-	1	(86)			
INCOME (LOSS) FROM CONTINUING OPERATIONS							
BEFORE INCOME TAXES	43	57	148	(63)			
Income tax expense	23	9	53	8			
INCOME (LOSS) FROM CONTINUING OPERATIONS	20	48	95	(71)			
Income from discontinued operations (net of income taxes)	2	-	13	-			
NET INCOME (LOSS)	\$ 22	\$ 48	\$ 108	\$ (71)			
DILUTED EARNINGS PER SHARE							
Income (loss) from continuing operations	\$.25	\$.65	\$ 1.21	\$ (1.00)			
Income from discontinued operations	.02	-	.16	-			
Net income (loss)	\$.27	\$.65	\$ 1.37	\$ (1.00)			
AVERAGE COMMON SHARES AND ASSUMED CONVERSIONS	80	74	79	71			
SALES							
Functional Ingredients	\$ 240	\$ 223	\$ 450	\$ 342			
Water Technologies	449	433	892	751			
Performance Materials	304	259	576	583			
Consumer Markets	430	407	830	795			
Distribution	857	698	1,586	1,551			
Intersegment sales	(32)	(30)	(66)	(66)			
	\$ 2,248	\$ 1,990	\$ 4,268	\$ 3,956			
OPERATING INCOME (LOSS)							
Functional Ingredients	\$ 34	\$ (3)	\$ 61	\$ (10)			
Water Technologies	31	13	70	7			
Performance Materials	6	5	14	11			
Consumer Markets	69	66	136	85			
Distribution	17	31	22	40			
Unallocated and other	(6)	-	(6)	(28)			
	\$ 151	\$ 112	\$ 297	\$ 105			

(a) The three and six months ended March 31, 2009 includes a \$5 million and \$31 million severance charge within the selling, general and administrative expenses caption for the ongoing integration and reorganization from the Hercules acquisition and other cost reduction programs and a \$16 million and \$37 million charge recorded within the cost of sales caption for a one-time fair value assessment of Hercules inventory as of the date of the transaction.

(b) The six months ended March 31, 2009 includes a \$10 million charge related to the valuation of the ongoing research and development projects at Hercules as of the acquisition date. In accordance with applicable GAAP and SEC accounting regulations, these purchased in-process research and development costs should be expensed upon acquisition.

(c) The three and six months ended March 31, 2010 includes a \$88 million charge related to the refinancing and significant extinguishment of debt completed during this period.

(d) The six months ended March 31, 2009 includes a \$54 million loss on currency swaps related to the Hercules acquisition and a \$32 million loss on auction rate securities.

(e) Results from November 14, 2008 forward include operations acquired from Hercules Incorporated.

Ashland Inc. and Consolidated Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS (In millions - preliminary and unaudited)

Current assets\$ 499\$ 203Cash and cash equivalents1,4941,357Inventories581579Deferred income taxes98Other current assets61Current assets61Account's receivable2,735Auction rate securities862,1672,074Intangibles1,150Auction rate securities862,1672,074Intangibles1,150Asbestos insurance receivable4784404,681Deferred income taxes91Other noncurrent assets545Noncurrent assets held for sale239693Noncurrent assets5451011,293Asbestos insurance receivable4,5404,681-Property, plant and equipmentCost3,386Accumulated depreciation and amortization(1,422)(1,264)1,9642,146Total assets\$ 9,239S 9,239\$ 9,237Current liabilities1,056Short-term debt23Current liabilities1,056Accured expenses and other liabilitiesAccured expenses and other liabilitiesLong-term debt1,126Current liabilities-Long-term debt1,126Current liabilities-Long-term debt2,369Long-term debt-Long-term debt-Long-term deb		March 31		
Current assets\$ 499\$ 203Cash and cash equivalents1,4941,357Inventories581579Deferred income taxes9893Other current assets6175Current assets6175Current assets6175Auction rate securities86214Goodwill2,1672,074Intangibles1,1501,293Asbestos insurance receivable478440Deferred income taxes91-Other noncurrent assets91-Other noncurrent assets545564Noncurrent assets held for sale2386Voncurrent assets545544Noncurrent assets545544Noncurrent assets91-Other noncurrent assets91-Other noncurrent assets91-Cost33863,410Accumulated depreciation and amortization(1,422)(1,264)1,9642,146Total assets\$ 9,239\$ 9,237Current liabilities3,39\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accured expenses and other liabilities-16LUNg-term debt2,054-Long-term debt2,054-Long-term debt573540Long-term debt-11,01Long-term debt-218Long-term debt </th <th></th> <th>2010</th> <th>2009</th>		2010	2009	
Cash and cash equivalents \$ 499 \$ 203 Accounts receivable 1,494 1,357 Inventories 581 579 Deferred income taxes 98 93 Other current assets 61 75 Current assets held for sale 2 93 Auction rate securities 86 214 Goodwill 2,167 2,074 Intrangibles 1,150 1,293 Abbesto insurance receivable 478 440 Deferred income taxes 91 - Other noncurrent assets 545 584 Noncurrent assets held for sale 23 86 Zotter assets 545 584 Noncurrent assets held for sale 23 86 Cost 3,386 3,410 Accumulated depreciation and amortization (1,422) (1,264) Current liabilities \$ 9,239 \$ 9,237 LIABILITIES AND STOCKHOLDERS' EQUITY 23 94 Current liabilities 440 457	ASSETS			
Accounts receivable1,4641,357Inventories581579Deferred income taxes9893Other current assets6175Current assets held for sale293Auction rate securities86214GoodWill2,1672,074Intangibles1,1501,293Asbestos insurance receivable478440Deferred income taxes91-Other noncurrent assets545564Noncurrent assets held for sale2386Other noncurrent assets545564Noncurrent assets held for sale2386Property, plant and equipment Cost3,3863,410Accumulated depreciation and amortization $(1,422)$ $(1,224)$ $(1,224)$ $(1,264)$ Total assets\$ 9,239\$ 9,237LABILITIES AND STOCKHOLDERS' EQUITY Current liabilities339\$ 84Current liabilities440457Current liabilities held for sale-1,066Noncurrent liabilities440457Current liabilities440457Current liabilities1,1012,084Long-term debt1,26667Asbestos litigation reserve89778Asbestos litigation reserve89768Deferred income taxes-218Other noncurrent liabilities573540Long-term debt1,26667Asbestos litigation reserve89773 <td< td=""><td>Current assets</td><td></td><td></td></td<>	Current assets			
Inventories581579Deferred income taxes9893Other current assets6175Current assets6175Current assets293Auction rate securities86214Goodwill2,1672,074Intangibles1,1501,293Absetos insurance receivable478440Deferred income taxes91-Other noncurrent assets545554Noncurrent assets held for sale2386Property, plant and equipment3,3863,410Cost3,3863,410Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITY2394Current liabilities440457Current liabilities440457Current liabilities440457Current liabilities440457Current liabilities440457Current liabilities440457Current liabilities440457Current liabilities1,1012,084Engloyee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes- 2183,682Other noncurrent liabilities573540Long-tern debt573540Current liabilities3,6823,543				
Deferred income taxes 98 93 Other current assets 61 75 Current assets held for sale 2 2,735 2,400 Noncurrent assets 86 214 Auction rate securities 86 214 Goodvill 2,167 2,074 Intangibles 1,150 1,293 Asbestos insurance receivable 478 440 Deferred income taxes 91 - Other noncurrent assets 545 584 Noncurrent assets held for sale 4,691 - Property, plant and equipment 23 86 - Cost 3,386 3,410 - - Accumulated depreciation and amortization (1,224) - 2,146 Total assets \$ 9,239 \$ 9,237 - - LIABILITIES AND STOCKHOLDERS' EQUITY - - - - Current liabilities \$ 339 \$ 84 - - - Current liabilities 1,056 -				
Other current assets 61 75 2Current assets 2 93 Auction rate securities 86 214 Goodwill $2,167$ $2,074$ Intangibles $1,150$ $1,293$ Asbestos insurance receivable 478 400 Deferred income taxes 91 $-$ Other noncurrent assets 545 564 Noncurrent assets held for sale 23 86 Property, plant and equipment 233 86 Cost $3,386$ $3,410$ Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets $$9,239$ $$9,237$ LIABILITIES AND STOCKHOLDERS' EQUITY 23 94 Trade and other payables $1,056$ 738 Accured expenses and other liabilities 440 457 Current liabilities 440 457 Current liabilities $1,101$ $2,084$ Employee benefit obligations $1,126$ 667 Asbestos litigation reserve 899 766 Deferred income taxes -218 $3,682$ Other noncurrent liabilities -218 -218 Other noncurrent liabilities -218 -218 Other noncurrent liabilities				
Current assets held for sale $\frac{2}{2,735}$ $\frac{93}{2,400}$ Noncurrent assetsAuction rate securities86214Goodwill2,1672,074Intangibles1,1501,293Asbestos insurace receivable478440Deferred income taxes91-Other noncurrent assets545564Noncurrent assets held for sale23862014,5404,691Property, plant and equipment3,3863,410Cost3,3863,410Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITY2394Current portion of long-term debt2394Trade and other payables1,056738Accured expenses and other liabilities440457Current liabilities440457Current liabilities1,1012,084Employee benefit obligations1,1012,084Employee benefit obligations1,126667Astestos litigation reserve899766Deferred income taxes-218Other noncurrent liabilitiesLong-term debt573540Stockholders' equity3,6823,543				
Noncurrent assets Auction rate securities $2,735$ $2,400$ Noncurrent assets Goodwill $2,167$ $2,074$ Intangibles Asbestos insurance receivable $1,150$ $1,293$ Asbestos insurance receivable 478 440 Deferred income taxes 91 $-$ Other noncurrent assets 545 584 Noncurrent assets held for sale 23 86 Property, plant and equipment Cost $3,386$ $3,410$ Accumulated depreciation and amortization $(1,422)$ $(1,244)$ $(1,264)$ $(1,264)$ Total assets $\$$ 9,239 $\$$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities $\$$ 339 $\$$ 84 440 Current liabilities 440 457 $1,056$ Noncurrent liabilities 440 457 $1,858$ Noncurrent liabilities $1,011$ $2,084$ $2,084$ $1,126$ Current liabilities $1,101$ $2,084$ $2,084$ $1,126$ Stockholders' equity $3,682$ $3,543$				
Noncurrent assets 86 214 Goodwill 2,167 2,074 Intangibles 1,150 1,293 Asbestos insurance receivable 478 440 Deferred income taxes 91 - Other noncurrent assets 545 584 Noncurrent assets held for sale 23 86 Property, plant and equipment 3,386 3,410 Cost 3,386 3,410 Accumulated depreciation and amortization (1,422) (1,264) Total assets \$ 9,239 \$ 9,237 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities \$ 339 \$ 84 Current portion of long-term debt 23 94 Trade and other payables 1,056 738 Accured expenses and other liabilities 440 457 Current liabilities 1,101 2,084 Employee benefit obligations 1,126 667 Asbestos litigation reserve 899 76 Deferred income taxes - 218 Other noncurrent liabilities - 218 LIMBLITIES	Current assets held for sale			
Auction rate securities 86 214 Goodwill2,1672,074Intangibles1,1501,293Asbestos insurance receivable 478 440 Deferred income taxes91-Other noncurrent assets 545 584 Noncurrent assets held for sale 23 86 Property, plant and equipment 23 86 Cost $3,386$ $3,410$ Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets $\$$ $9,239$ $\$$ $9,237$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities 440 457 Current portion of long-term debt 23 94 Trade and other payables $1,056$ 738 Accrued expenses and other liabilities 440 457 Current liabilities 23 94 Trade and other payables $1,056$ Accrued expenses and other liabilities 440 Long-term debt $1,126$ Current liabilities 23 Current liabilities 23 Current liabilities 23 Current liabilities 23 Current liabilities 440 Current liabilities 23 Current liabilities 23 Current liabilities 23 Current liabilities<		2,735	2,400	
Auction rate securities 86 214 Goodwill2,1672,074Intangibles1,1501,293Asbestos insurance receivable 478 440 Deferred income taxes91-Other noncurrent assets 545 584 Noncurrent assets held for sale 23 86 Property, plant and equipment 23 86 Cost $3,386$ $3,410$ Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets $\$$ $9,239$ $\$$ $9,237$ LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities 440 457 Current portion of long-term debt 23 94 Trade and other payables $1,056$ 738 Accrued expenses and other liabilities 440 457 Current liabilities 23 94 Trade and other payables $1,056$ Accrued expenses and other liabilities 440 Long-term debt $1,126$ Current liabilities 23 Current liabilities 23 Current liabilities 23 Current liabilities 23 Current liabilities 440 Current liabilities 23 Current liabilities 23 Current liabilities 23 Current liabilities<	Noncurrent assets			
Goodwill2,1672,074Intangibles1,1501,293Asbestos insurance receivable478440Deferred income taxes91-Other noncurrent assets545584Noncurrent assets held for sale23864,5404,6914,691Property, plant and equipment $(1,422)$ $(1,264)$ Cost3,3863,410Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets§ 9,239§ 9,237LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities1,056Current portion of long-term debt2394Trade and other payables1,056738Accurued expenses and other liabilities440457Current liabilities1,1012,084Long-term debt1,126667Current liabilities1,126667Long-term debt1,126667Current liabilities1,126667Long-term debt1,226677Current liabilities2,2992,216Long-term debt1,26667Stockholders' equity3,6823,543		86	214	
Intagibles1,1501,293Asbestos insurance receivable478440Deferred income taxes91-Other noncurrent assets545584Noncurrent assets held for sale 23 86 4,5404,6914,691Property, plant and equipment Cost $3,386$ $3,410$ Accumulated depreciation and amortization $(1,422)$ $(1,224)$ Total assets $$ 9,239$ $$ 9,237$ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities $$ 339$ $$ 84$ Current portion of long-term debt $$ 339$ $$ 84$ Current liabilities 440 457 Current liabilities 440 457 Current liabilities 440 457 Current liabilities 440 457 Current liabilities 410 457 Current liabilities 410 457 Current liabilities 410 457 Current liabilities 410 457 Current liabilities 440 457 Current liabilities 410 457 Current liabilities 410 457 Current liabilities $1,101$ $2,084$ Long-term debt $1,126$ 677 Asbestos litigation reserve 899 796 Deferred income taxes $ 218$ Other noncurrent liabilities 533 540 Asbestos litigation reserve 899 796 Deferred income taxes $ 218$ Other noncurren				
Asbestos insurance receivable478440Deferred income taxes91-Other noncurrent assets545584Noncurrent assets held for sale 23 86 4,540 $4,691$ Property, plant and equipment $3,386$ $3,410$ Cost $3,386$ $3,410$ Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets $\frac{5}{9,239}$ $\frac{9,237}{9,237}$ LIABILITIES AND STOCKHOLDERS' EQUITY 23 94Current liabilities $1,056$ 738 Short-term debt 23 94Trade and other payables $1,056$ 738 Accrued expenses and other liabilities 440 457 Current liabilities 440 457 Current liabilities $1,101$ $2,084$ Employee benefit obligations $1,126$ 667 Asbestos litigation reserve 899 796 Deferred income taxes $ 218$ Other noncurrent liabilities 573 540 Stockholders' equity $3,682$ $3,543$				
Other noncurrent assets545584Noncurrent assets held for sale $\frac{23}{4,540}$ $\frac{86}{4,691}$ Property, plant and equipment Cost $3,386$ $3,410$ Accumulated depreciation and amortization $(1,422)$ $(1,264)$ Total assets $\frac{9,239}{2,237}$ $\frac{9,239}{2,237}$ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilitiesShort-term debt $\frac{3}{23}$ 94 Trade and other payables $1,056$ 738 Accurued expenses and other liabilities 440 457 Current liabilities $\frac{1}{1,056}$ 738 Accured expenses and other liabilities $\frac{1}{1,056}$ $1,858$ Long-term debt $\frac{1}{1,858}$ $\frac{1}{1,389}$ Noncurrent liabilities $\frac{1}{1,101}$ $2,084$ Employee benefit obligations $\frac{1}{1,26}$ 667 Asbestos litigation reserve 899 796 Deferred income taxes -218 $\frac{3}{3,699}$ Other noncurrent liabilities $\frac{5}{3,399}$ $\frac{4}{3,305}$ Stockholders' equity $3,682$ $3,543$	-			
Noncurrent assets held for sale2386Property, plant and equipment Cost3,3863,410Accumulated depreciation and amortization(1,422)(1,264)Accumulated depreciation and amortization(1,422)(1,264)Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilitiesCurrent portion of long-term debt\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accurrent liabilities440457Current liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543	Deferred income taxes	91	-	
Interaction and another hand to the last of the l	Other noncurrent assets	545	584	
Property, plant and equipment Cost3,3863,410Accumulated depreciation and amortization(1,422) (1,264)(1,264) (1,264)Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Short-term debt\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities-16Current liabilities-16Noncurrent liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543	Noncurrent assets held for sale	23	86	
Cost3,3863,410Accumulated depreciation and amortization(1,422)(1,264)1,9642,146Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilitiesCurrent portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilitiesCurrent liabilities-16Noncurrent liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543		4,540	4,691	
Cost3,3863,410Accumulated depreciation and amortization(1,422)(1,264)1,9642,146Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilitiesCurrent portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilitiesCurrent liabilities-16Noncurrent liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543				
Accumulated depreciation and amortization(1,422) 1,964(1,264) 2,146Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Short-term debt\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities-16Total assets1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543				
Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities-16T,8581,389Noncurrent liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543				
Total assets\$ 9,239\$ 9,237LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities440457Current liabilities-16I,8581,389Noncurrent liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543	Accumulated depreciation and amortization			
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Short-term debtShort-term debt\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities held for sale-16Noncurrent liabilities1,1012,084Long-term debt1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543		1,964	2,146	
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Short-term debtShort-term debt\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities held for sale-16Noncurrent liabilities1,1012,084Long-term debt1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543	Total assets	\$ 9,239	\$ 9237	
Current liabilities\$ 339\$ 84Short-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities held for sale-161,8581,389Noncurrent liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543		• •,200	• •,201	
Short-term debt\$ 339\$ 84Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities held for sale-161,8581,389Noncurrent liabilities1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543	LIABILITIES AND STOCKHOLDERS' EQUITY			
Current portion of long-term debt2394Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities held for sale-161,8581,389Noncurrent liabilities1,1012,084Long-term debt1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities573540Stockholders' equity3,6823,543	Current liabilities			
Trade and other payables1,056738Accrued expenses and other liabilities440457Current liabilities held for sale-161,8581,389Noncurrent liabilities1,1012,084Long-term debt1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,3053,6823,543	Short-term debt	\$ 339	\$ 84	
Accrued expenses and other liabilities440457Current liabilities held for sale-161,8581,389Noncurrent liabilities1,1012,084Long-term debt1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,3053,6823,543				
Current liabilities held for sale-161,8581,389Noncurrent liabilities Long-term debt1,1012,084Employee benefit obligations Asbestos litigation reserve1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,3053,6823,543				
Noncurrent liabilitiesLong-term debt1,101Employee benefit obligations1,126Asbestos litigation reserve899Deferred income taxes-Other noncurrent liabilities573Stockholders' equity3,6823,6823,543		440		
Noncurrent liabilities1,1012,084Long-term debt1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,305Stockholders' equity3,6823,543	Current liabilities held for sale	-		
Long-term debt1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,3053,6823,543		1,858	1,389	
Long-term debt1,1012,084Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,3053,6823,543	Noncurrent liabilities			
Employee benefit obligations1,126667Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,305Stockholders' equity3,6823,543		1 101	2 094	
Asbestos litigation reserve899796Deferred income taxes-218Other noncurrent liabilities5735403,6994,305Stockholders' equity3,6823,543				
Deferred income taxes - 218 Other noncurrent liabilities 573 540 3,699 4,305 Stockholders' equity 3,682 3,543				
Other noncurrent liabilities 573 540 3,699 4,305 Stockholders' equity 3,682 3,543				
3,699 4,305 Stockholders' equity 3,682 3,543		573		
Stockholders' equity 3,682 3,543				
		-,000	.,	
Total liabilities and stockholders' equity \$ 9.239 \$ 9.237	Stockholders' equity	3,682	3,543	
	Total liabilities and stockholders' equity	\$ 9,239	\$ 9,237	

Ashland Inc. and Consolidated Subsidiaries
STATEMENTS OF CONSOLIDATED CASH FLOWS
(In millions - preliminary and unaudited)

(In millions - preliminary and unaudited)	-	
		ths ended rch 31
	2010	2009
CASH FLOWS PROVIDED BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS		
Net income (loss) Income from discontinued operations (net of income taxes)	\$ 108	\$ (71)
Adjustments to reconcile income (loss) from continuing operations to	(13)	-
cash flows from operating activities		
Depreciation and amortization	153	156
Debt issuance cost amortization	74	16
Purchased in-process research and development amortization Deferred income taxes	55	10 2
Equity income from affiliates	(12)	(7)
Distributions from equity affiliates	6	4
Gain from sale of property and equipment	(4)	-
Stock based compensation expense	7	3
Stock contributions to qualified savings plans	13 5	4
Net loss on divestitures Loss on early retirement of debt	5	-
Inventory fair value adjustment related to Hercules acquisition		37
Loss on currency swaps related to Hercules acquisition	-	54
(Gain) loss on auction rate securities	(1)	32
Change in operating assets and liabilities (a)	(177)	54
	218	294
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS Additions to property, plant and equipment	(60)	(80)
Proceeds from disposal of property, plant and equipment	(00)	(00)
Purchase of operations - net of cash acquired	-	(2.078)
Proceeds from sale of operations	60	7
Settlement of currency swaps related to Hercules acquisition	-	(95)
Proceeds from sales and maturities of available-for-sale securities	85	29
CARLELOWS (USED) DROMPED BY ENJANCING ACTIVITIES FROM CONTINUING ODERATIONS	94	(2,213)
CASH FLOWS (USED) PROVIDED BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS Proceeds from issuance of long-term debt	300	2.000
Repayment of long-term debt	(773)	2,000 (645)
Proceeds from/repayments of issuance of short-term debt	317	43
Debt issuance costs	(12)	(137)
Cash dividends paid	(12)	(11)
Proceeds from exercise of stock options	4	-
Excess tax benefits related to share-based payments	1	
CASH PROVIDED (USED) BY CONTINUING OPERATIONS	(175) 137	1,250 (669)
Cash provided by discontinued operations	157	(009)
Operating cash flows	12	3
Effect of currency exchange rate changes on cash and cash equivalents	(2)	(17)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	147	(683)
Cash and cash equivalents - beginning of year	352	886
CASH AND CASH EQUIVALENTS - END OF PERIOD	\$ 499	\$ 203
DEPRECIATION AND AMORTIZATION		
Functional Ingredients	\$ 51	\$ 49
Water Technologies	46	41
Performance Materials	24	27
Consumer Markets	18	18
Distribution Unallocated and other	14	15 6
Challocated and other	\$ 153	\$ 156
ADDITIONS TO PROPERTY, PLANT AND EQUIPMENT		
Functional Ingredients	\$ 25	\$ 27
Water Technologies	11	9
Performance Materials	7	18
Consumer Markets Distribution	9	15 1
Unallocated and other	7	10
	\$ 60	\$ 80
(a) Excludes changes resulting from operations acquired or sold.		

(a) Excludes changes resulting from operations acquired or sold.

Ashland Inc. and Consolidated Subsidiaries INFORMATION BY INDUSTRY SEGMENT (In millions - preliminary and unaudited)

Three months ended				Six months ended			
March 31				March 31			
2010		010 2		2010		2009	
\$	3.8	\$	3.5	\$	3.6	\$	3.7
	41.9		46.4		79.3		70.8
	34.9%		22.4%		34.3%		20.0%
\$	7.1	\$	6.9	\$	7.1	\$	6.0
	34.5%		32.6%		35.5%		31.6%
\$	4.8	\$	4.1	\$	4.6	\$	4.7
	4.4		3.7		4.2		4.0
	16.5%		19.5%		17.4%		17.5%
	43.7		37.7		83.9		70.7
	29.6%		29.1%		29.0%		28.2%
	33.0%		32.2%		33.4%		27.1%
\$	13.6	\$	11.1	\$	12.7	\$	12.4
	15.4		14.3		14.9		14.9
	9.3%		12.8%		9.3%		10.5%
	\$	Marc 2010 \$ 3.8 41.9 34.9% \$ 7.1 34.5% \$ 4.8 4.4 16.5% 43.7 29.6% 33.0% \$ 13.6 15.4	March 31 2010 \$ 3.8 \$ 41.9 34.9% \$ 7.1 \$ 34.5% \$ 4.8 \$ 4.4 16.5% 43.7 29.6% 33.0% \$ 13.6 \$ 15.4	March 31 2010 2009 \$ 3.8 \$ 3.5 41.9 46.4 34.9% 22.4% \$ 7.1 \$ 6.9 34.5% 32.6% \$ 4.8 \$ 4.1 4.4 3.7 16.5% 19.5% 43.7 37.7 29.6% 29.1% 33.0% 32.2% \$ 13.6 \$ 11.1 15.4 14.3	March 31 2010 2009	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$

(a) Sales are defined as net sales. Gross profit as a percent of sales is defined as sales, less cost of sales divided by sales.

\$

(3)

\$

(b) Industry segment results from November 14, 2008 forward include operations acquired from Hercules Incorporated.

(c) Distribution's gross profit as a percentage of sales for the three and six months ended March 31, 2009 includes a LIFO quantity credit of \$11 million.

Ashland Inc. and Consolidated Subsidiaries

INCOME (LOSS) FROM CONTINUING OPERATIONS

RECONCILIATION OF NON-GAAP DATA - INCOME (LOSS) FROM CONTINUING OPERATIONS (In millions - preliminary and unaudited)

Three Months Ended March 31, 2010 Functional Water Performance Consume Unallocated Ingredients Technologies Materials Markets Distribution & Other Total **OPERATING INCOME (LOSS)** All other operating income (loss) 69 s 31 S 6 s s 17 s (6) s 151 s 34 NET INTEREST AND OTHER FINANCING EXPENSE Accelerated amortization of debt issuance costs (62) (62) Loss on early debt retirement (4) (4) All other net interest and other financing expense (37) (37) NET LOSS ON DIVESTITURES Medicare Part D accrual for MAP retirees (5) (5) INCOME TAX EXPENSE Medicare Part D deferred tax accrual (14) (14) All other income tax expense (9) (9) (23)(23)69 INCOME (LOSS) FROM CONTINUING OPERATIONS 17 (137) 20 34 31 \$ \$ \$ S \$ 6 \$ - 5

Three Months Ended March 31, 2009 Functional Water Performance Consume Unallocated Ingredients Technologies Materials Markets Distribution & Other Total OPERATING INCOME (LOSS) (1)Severance s s . s (3) s s . s (1) s (5)Inventory fair value adjustment (16) (16)(2) (4) (6) Asset impairments and accelerated depreciation 5 5 Currency gain on intracompany loan All other operating income 14 13 10 66 31 134 Operating income (loss) (3) 13 5 66 31 -112 NET INTEREST AND OTHER FINANCING EXPENSE (54) (54)NET LOSS ON DIVESTITURES (1) (1) INCOME TAX EXPENSE (9) (9)

13 \$ 5 \$

66 \$

31 \$

(64)

\$

48

Table 5

Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF NON-GAAP DATA - FREE CASH FLOW (In millions - preliminary and unaudited)

	Three months ended March 31				Six months ended March 31			nded
Free cash flow	2010 2009			2010		2009		
Total cash flows provided by operating activities								
from continuing operations	\$	183	\$	220	\$	218	\$	294
Less:								
Additions to property, plant and equipment		(39)		(42)		(60)		(80)
Cash dividends paid		(6)		(5)		(12)		(11)
Free cash flows	\$	138	\$	173	\$	146	\$	203

Ashland Inc. and Consolidated Subsidiaries RECONCILIATION OF NON-GAAP DATA - ADJUSTED EBITDA (In millions - preliminary and unaudited)

Three months ended March 31 Adjusted EBITDA - Ashland Inc. 2010 2009 \$ Operating Income 151 S 112 Add: Depreciation and amortization 73 93 16 Key items (see Table 5) Adjusted EBITDA 224 221 \$ S Adjusted EBITDA - Ashland Aqualon Functional Ingredients Operating Income \$ 34 (3) \$ Add: 33 Depreciation and amortization 24 Key items (see Table 5) 17 Adjusted EBITDA 58 S 47 S Adjusted EBITDA - Water Technologies 13 Operating Income \$ 31 \$ Add: Depreciation and amortization 21 25 Key items (see Table 5) Adjusted EBITDA 52 38 \$ \$ Adjusted EBITDA - Performance Materials Operating Income \$ 6 5 \$ Add: Depreciation and amortization 12 13 Key items (see Table 5) 5 Adjusted EBITDA 18 23 Adjusted EBITDA - Consumer Markets \$ 66 Operating Income 69 \$ Add: Depreciation and amortization 9 9 Key items (see Table 5) Adjusted EBITDA 78 75 \$ \$ Adjusted EBITDA - Distribution Operating Income S 17 31 s Add: 7 7 Depreciation and amortization Key items (see Table 5) Adjusted EBITDA 24 38 S \$

SOURCE Ashland Inc.

Table 6

Table 7